Leap Therapeutics Inc (NAS:LPTX)

$ 2.38 -0.09 (-3.64%) Market Cap: 91.07 Mil Enterprise Value: 36.73 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 46/100

Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast Transcript
Jan 23, 2024
Leap Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 13, 2023
Leap Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Leap Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2023
Leap Therapeutics Inc Acquires Flame Biosciences Transcript
Jan 17, 2023
Leap Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Leap Therapeutics Inc - R&D Day Transcript
Jul 12, 2022
Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call Transcript
Jan 21, 2022
Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call Transcript
Sep 17, 2021
Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Leap Therapeutics Inc DKN-01 Clinical Data Conference Call Transcript
Mar 22, 2021
Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Leap Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Leap Therapeutics, Inc. - Special Call Transcript
Apr 23, 2020
Leap Therapeutics, Inc. - Special Call Transcript
Aug 06, 2019

Leap Therapeutics, Inc. - Special Call Transcript

Aug 06, 2019 / 12:30PM GMT

Release Date Price: $17.7 (-14.90%)

Transcript 8-K10-Q

Operator

Good day, everyone, and welcome to the Leap Therapeutics DKN-01 Clinical Investigator Conference Call. Following the presentation, there will be an opportunity for questions. Please be advised that this call is being recorded at the company's request. At this time, I will now turn the call over to Dr. Cynthia Sirard, Vice President of Clinical Research and Development of Leap. Please begin.

Cynthia A. Sirard

Leap Therapeutics, Inc. - VP of Clinical Development

Thank you, operator. Welcome and thank you to those of you joining us today for an update on LEAP Therapeutics DKN-01 development program. I'm Cynthia Sirard; and with me today are Douglas Onsi, the Chief Financial Officer of Leap; Walter Newman, Vice President of Research at Leap; Dr. Samuel Klempner, an Assistant Professor of Massachusetts General Hospital Cancer Center and Harvard Medical School; and Dr. Rebecca Arend, an Assistant Professor and Associate Scientist at Gynecologic Oncology Clinic, University of Alabama Comprehensive Cancer Center Experimental Therapeutics Program.

This call is

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.